Richard Geary

Richard Geary, Ph.D., is the Executive Vice President and Chief Development Officer at Ionis Pharmaceuticals, Inc. He has held this position since joining the company in 1995, where he has been instrumental in the development of antisense medicines. His responsibilities encompass preclinical and clinical development, regulatory affairs, and clinical-stage manufacturing.12

Educational Background

• Ph.D. in Biopharmaceutics from the University of Texas, College of Pharmacy.
• B.S. in Biology from Texas A&M University.13

Professional Achievements

• Dr. Geary has overseen the regulatory submission of over 40 investigational new drug applications to various regulatory agencies.
• He has led the late-stage development of four antisense medicines that achieved approvals in multiple jurisdictions.12
• His scholarly contributions include 14 book chapters and more than 80 peer-reviewed manuscripts, focusing on the pharmacokinetics and metabolism of antisense therapies.12

Affiliations

In addition to his role at Ionis, Dr. Geary serves on the Board of Directors for the Oligonucleotide Therapeutics Society and co-leads its publication committee for Nucleic Acid Therapeutics.12

Dr. Geary's extensive experience and leadership in drug development make him a significant figure in the biopharmaceutical industry, particularly in RNA-targeted therapies.